INCY250117P80000
- 7.60
- 0.000.00%
Incyte Newsroom
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
Express News | Incyte : RBC Cuts Target Price to $70 From $75
Wall Street Today: AI Domestic Investment News on the Way
Live Stock News: Market Climbs, Crypto Falls, Big Tech is Here and Trump Starts Signing Orders
Press Release: Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
Incyte Insiders Sell US$4.7m Of Stock, Possibly Signalling Caution
Weekly Buzz: Finally a Good Week for 2025
Wall Street Today: Trump's on Deck After Market Nearly Hits Year High
Live Stock News: Market Climbs, TikTok Ban Confirmed, Intel for Sale, Week Ends with Positivity
Wall Street Today: Thursday Earnings Looked a Lot More Mixed, and Philly is Booming
Live Stock News: Sideways Trading Market After Big TSMC, UNH Earnings, Philly Economy is Booming
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
Express News | Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
Express News | Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (Axatilimab-csfr) 9 Mg and 22 Mg Vial Sizes
Wall Street Today: JPM and Banking Leads Market Higher
Live Stock: Banks Break the Bank on Earnings, Inflation Looks Tame for Dec
JP Morgan 2025: Incyte Expects Period of 'Defining Catalysts'